ArticleMMWR. Morbidity and mortality weekly report2023
Health Care Provider Knowledge Regarding Alpha-gal Syndrome - United States, March-May 2022.
Article in MMWR. Morbidity and mortality weekly report, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Alpha-Gal Syndrome Is More than Meats the IgE: A Patient Survey of Symptoms, Diagnosis, and Burdens.Healthcare (Basel, Switzerland) · 2026Article
- Article
- Alpha-gal Syndrome Symptom Profiles and Diagnostic Experiences Among Farmer and Ranchers.medRxiv : the preprint server for health sciences · 2026Article
- From vector to allergen: exploring the immunology of tick-triggered α-Gal syndrome.Frontiers in immunology · 2026Review
- Isolated Gastrointestinal Presentations in Alpha-Gal Syndrome: A Distinct Clinical Phenotype With High Endoscopic Utilization.Gastro hep advances · 2026Review
- Nutritional considerations for alpha-gal syndrome: a mini-review.Frontiers in allergy · 2026Review
- Childhood-onset alpha-gal syndrome in the central black sea region: real-world data on diagnostic delays, age-specific clinical patterns, environmental risk factors, and anaphylaxis predictors.European journal of pediatrics · 2025Article
- Alpha-Gal Syndrome in the Heartland: Dietary Restrictions, Public Awareness, and Systemic Barriers in Rural Kansas.Nutrients · 2025Article
- A Review of Alpha-Gal Syndrome for the Infectious Diseases Practitioner.Open forum infectious diseases · 2025Review
- The Immunology of Alpha-Gal Syndrome: History, Tick Bites, IgE, and Delayed Anaphylaxis to Mammalian Meat.Immunological reviews · 2025Review
- Is Zebrafish a Good Model for the Alpha-Gal Syndrome?FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Time From Onset to Diagnosis of Alpha-Gal Syndrome.JAMA network open · 2025Article
- Article
- Alpha Guy? No, Alpha Gal-Important to Remember in Patients with IBD in Endemic Areas.Digestive diseases and sciences · 2025Article
- Prior knowledge and perceived impacts of tick-borne disease education among indigenous bison workers at an annual roundtable training.Frontiers in public health · 2025Article
- Alpha-gal syndrome and the gastrointestinal reaction: a narrative review.Frontiers in allergy · 2025Review
- Alpha-Gal Syndrome: Often Hidden, Under-Recognized, and in Need of Attention-A Rapid Review.International journal of general medicine · 2025Review
- Incidence of Alpha-Gal IgE Sensitization in 3000 Military Personnel, Assessing Sex, Race, Installation, and Occupational Impacts.Journal of clinical medicine · 2024Article
- Sensitization to α-gal and omega-5-gliadin in patients with chronic urticaria: clinical implications and need for targeted testing.Postepy dermatologii i alergologii · 2024Article
- Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-gal syndrome (AGS) is an emerging, tick bite-associated immunoglobulin E-mediated allergic condition characterized by a reaction to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal), which is found in mammalian meat and products derived from mammals, including milk, other dairy products, and some pharmaceutical products. Symptoms range from mild (e.g., a rash or gastrointestinal upset) to severe (anaphylaxis); onset typically occurs ≥2 hours after exposure to alpha-gal. No treatment or cure is currently available. Despite the potential life-threating reactions associated with AGS, most patients perceive that health care providers (HCPs) have little or no knowledge of AGS. A U.S. web-based survey of 1,500 HCPs revealed limited knowledge of AGS, identified areas for continuing medical education, and described self-reported diagnostic and management practices. Overall, 42% of surveyed HCPs had never heard of AGS, and among those who had, fewer than one third knew how to diagnose the condition. Two thirds of respondents indicated that guidelines for the diagnosis and management of AGS would be useful clinical resources. Limited awareness and knowledge of AGS among HCPs likely contributes to underdiagnosis of this condition and inadequate patient management, and underestimates of the number of AGS patients in the United States, which currently relies on laboratory testing data alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.